- Halozyme Therapeutics (NASDAQ:HALO) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close.
- The consensus EPS Estimate is $0.51 and the consensus Revenue Estimate is $191.17M (+296.6% Y/Y).
- Over the last 2 years, HALO has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 3 upward revisions and 3 downward.
Halozyme Therapeutics Q3 2022 Earnings Preview
Recommended For You
More Trending News
About HALO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HALO | - | - |
Halozyme Therapeutics, Inc. |